Literature DB >> 18034810

Partial splenic embolization.

Hiroshi Yoshida1, Yasuhiro Mamada, Nobuhiko Taniai, Takashi Tajiri.   

Abstract

Partial splenic embolization (PSE) is a non-surgical procedure developed to treat hypersplenism as a result of hepatic disease and thus avoid the disadvantages of splenectomy. A femoral artery approach is used for selective catheterization of the splenic artery. Generally, the catheter tip is placed as distally as possible in an intrasplenic artery. After an injection of antibiotics and steroids, embolization is achieved by injecting 2-mm gelatin sponge cubes suspended in a saline solution containing antibiotics. PSE can benefit patients with thrombocytopenia, esophagogastric varices, portal hypertensive gastropathy, encephalopathy, liver dysfunction, splenic aneurysm, and splenic trauma. The contraindications of PSE include secondary splenomegaly and hypersplenism in patients with terminal-stage underlying disease; pyrexia or severe infections are associated with a high risk of splenic abscess after PSE. Complications of PSE include daily intermittent fever, abdominal pain, nausea and vomiting, abdominal fullness, appetite loss, and postembolization syndrome. Decreased portal-vein flow and a rapid increase in the platelet count after excessive embolization may cause portal-vein or splenic-vein thrombosis.

Entities:  

Year:  2007        PMID: 18034810     DOI: 10.1111/j.1872-034X.2007.00302.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  35 in total

Review 1.  Management before hepatectomy for hepatocellular carcinoma with cirrhosis.

Authors:  Hisashi Nakayama; Tadatoshi Takayama
Journal:  World J Hepatol       Date:  2015-09-18

2.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

3.  Severe thrombocytopenia due to hypersplenism treated with partial splenic embolisation.

Authors:  Mohammad Hanafiah; Azura Mohamed Mukhari Shahizon; Soo Fin Low; Man Harun Shahrina
Journal:  BMJ Case Rep       Date:  2013-07-05

4.  Laparoscopic splenic vessels ligation as a treatment of hypersplenism and thrombocytopenia in children.

Authors:  Jin-Shan Zhang; Long Li; Qi Li; Wei Cheng
Journal:  Surg Endosc       Date:  2015-12-10       Impact factor: 4.584

5.  Which Arteries Are Expendable? The Practice and Pitfalls of Embolization throughout the Body.

Authors:  Thomas R Burdick; Eric K Hoffer; Todd Kooy; Basavaraj Ghodke; Benjamin W Starnes; Karim Valji; Steve Goldberg; Danial Hallam; R Torrance Andrews
Journal:  Semin Intervent Radiol       Date:  2008-09       Impact factor: 1.513

6.  Total embolization of the main splenic artery as a supplemental treatment modality for hypersplenism.

Authors:  Xin-Hong He; Wen-Tao Li; Wei-Jun Peng; Guo-Dong Li; Sheng-Ping Wang; Li-Chao Xu
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

7.  Radiofrequency ablation for treatment of hypersplenism: A feasible therapeutic option.

Authors:  Guilherme Lopes P Martins; Joao Paulo G Bernardes; Marcello S Rovella; Raphael G Andrade; Publio Cesar C Viana; Paulo Herman; Giovanni Guido Cerri; Marcos Roberto Menezes
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

8.  Partial embolization as re-treatment of hypersplenism after unsuccessful splenic artery ligation.

Authors:  Zheng-Ju Xu; Lian-Qiu Zheng; Xing-Nan Pan
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

9.  Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer.

Authors:  Timothy R Donahue; Kevork K Kazanjian; William H Isacoff; Howard A Reber; O Joe Hines
Journal:  J Gastrointest Surg       Date:  2010-03-23       Impact factor: 3.452

10.  Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention.

Authors:  Shogo Ohkoshi; Satoshi Yamagiwa; Masahiko Yano; Hiromichi Takahashi; Yo-Hei Aoki; Yasunobu Matsuda; Yutaka Aoyagi
Journal:  Case Rep Gastroenterol       Date:  2010-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.